123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations
Tóm tắt
Reduced uptake of 123I- metaiodobenzylguanidine (MIBG) on cardiac gammagraphy and impaired odor identification are markers of neurodegenerative diseases with Lewy bodies (LB) as a pathological hallmark, such as idiopathic Parkinson’s disease (IPD). LRRK2 patients present with a clinical syndrome indistinguishable from IPD, but LB have not been found in some cases. Patients with such mutations could behave differently than patients with IPD with respect to MIBG cardiac uptake and olfaction. We studied 14 LRRK2 patients, 14 IPD patients matched by age, gender, disease duration and severity, and 13 age and gender matched control subjects. Olfaction was analyzed through the University of Pennsylvania Smell Identification Test (UPSIT). MIBG cardiac uptake was evaluated through the H/M ratio. The late H/M was 1.44 ± 0.31 for LRRK2 patients, 1.19 ± 0.15 for PD patients, and 1.67 ± 0.16 for control subjects. LRRK2 patients presented lower but not statistically significant MIBG cardiac uptake than controls (p = 0.08) and significant higher uptake than PD patients (p = 0.04). UPSIT mean scores were 21.5 ± 7.3 for LRRK2 patients, 18.7 ± 6.2 for IPD patients and 29.7 ± 5.7 for control subjects. UPSIT score was lower in both LRRK2 and PD than in controls. In LRRK2 patients a positive correlation was found between myocardial MIBG uptake and UPSIT scores, (R = 0.801, p < 0.001). In LRRK2 patients, MIBG cardiac uptake was less impaired than in PD; a positive correlation between MIBG cardiac uptake and UPSIT scores was observed. As MIBG cardiac reduced uptake and impaired odor identification are markers of LB pathology, this findings may represent neuropathological heterogeneity among LRRK2 patients.
Tài liệu tham khảo
Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607
Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ et al (2005) A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 365:415–416
Gaig C, Ezquerra M, Martí MJ, Muñoz E, Valldeoriola F, Tolosa E (2006) LRRK2 mutations in Spanish patients with Parkinson’s disease: frequency, clinical features and incomplete penetrance. Arch Neurol 63:377–382
Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H et al (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57:918–921
Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ et al (2006) Biochemical and pathological characterization of LRRK2. Ann Neurol 59:315–322
Rajput A, Dickson DW, Robinson CA, Ross OA, Dächsel JC, Lincoln SJ et al (2006) LRRK2 G2019S, and tau neuropathology. Neurology 67:1506–1508
Gaig C, Marti MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E (2007) G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. J Neurol Neurosurg Psychiatry 78:626–628
Gaig C, Ezquerra M, Martí MJ, Valldeoriola F, Muñoz E, Lladó A et al (2008) Screening for the LRRK2 G2019S and codon-1,441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 270:94–98
Martí-Massó JF, Ruiz-Martínez J, Bolaño MJ, Ruiz I, Gorostidi A, Moreno F et al (2009) Neuropathology of Parkinson’s disease with the R1441G mutation in LRRK2. Mov Disord 24:1998–2001
Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T et al (2005) Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109:583–588
Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K et al (2007) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol 17:24–30
Orimo S, Oka T, Miura H, Tsuchiya K, Mori F, Wakabayashi K et al (2002) Sympathetic cardiac denervation in Parkinson’s disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 73:776–777
Orimo S, Ozawa E, Nakade S, Hattori H, Tsuchiya K, Takahashi A (2003) [123]MIBG myocardial scintigraphy differentiates corticobasal degeneration from Parkinson’s disease. Intern Med 42:127–128
Hawkes C (2004) Olfactory testing in parkinsonism. Lancet Neurol 3:393–394
Silveira-Moriyama L, Holton JL, Kingsbury A, Ayling H, Petrie A, Sterlacci W et al (2009) Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci Lett 453:77–80
Doty RL, Golbe LI, McKeown DA, Stern MB, Lehrach CM, Crawford D (1993) Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson’s disease. Neurology 43:962–965
McShane RH, Nagy Z, Esiri MM, King E, Joachim C, Sullivan N et al (2001) Anosmia in dementia is associated with Lewy bodies rather than Alzheimer’s pathology. J Neurol Neurosurg Psychiatry 70:739–743
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13:513–521
Lafreniere D, Mann N (2009) Anosmia: loss of smell in the elderly. Otolaryngol Clin North Am 41:123–131
Quattrone A, Bagnato A, Annesi G, Novellino F, Morgante L, Savettieri G et al (2008) Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson’s disease. Mov Disord 23:21–27
Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S et al (2006) Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson’s disease patients from 18 countries. Mov Disord 21:1102–1108
Silveira-Moriyama L, Guedes LC, Kingsbury A, Ayling H, Shaw K, Barbosa ER et al (2008) Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. Neurology 71:1021–1026
Orimo S, Amino T, Yokochi M, Kojo T, Uchihara T, Takahashi A et al (2005) Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord 20:1350–1353
Suzuki M, Hattori N, Orimo S, Fukumitsu N, Abo M, Kono Y et al (2005) Preserved 123I-metaiodbenzylguanidine uptake in autosomal recessive juvenile parkinsonism: first case report. Mov Disord 20:634–636
Khan NL, Katzenschlager R, Watt H, Batia KP, Wood NW, Quinn N et al (2004) Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 62:1224–1226
Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa Hattori Y, Miyake T et al (1998) Pathological and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51:890–892
Hayashi S, Wakabayashi K, Ishikawa A, Nagai H, Saito M, Muruyama M et al (2000) An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 15:884–888
Chen-Plotkin AS, Yuan W, Anderson C, Wood EM, Hurtig HI, Clark CM et al (2008) Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70:521–527
Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H (1999) 123I metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 67:189–194
Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL et al (2003) Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 18:890–897
Haensch CA, Lerch H, Jörg J, Isenmann S (2009) Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson’s disease. Parkinsonism Relat Disord 15:134–137
Louis ED, Marder K, Tabert MH, Devanand DP (2008) Mild Parkinsonian signs are associated with lower olfactory test scores in the community-dwelling elderly. Mov Disord 23:524–530
Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22:839–842
Iijima M, Osawa M, Momose M, Kobayakawa T, Saito S, Iwata M et al (2010) Cardiac sympathetic degeneration correlates with olfactory function in Parkinson’s disease. Mov Disord 25:1143–1149
Lee PH, Yeo SH, Kim HJ, Youm HY (2006) Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson’s disease and multiple system atrophy. Mov Disord 21:1975–1977
Goldstein DS, Sewell L, Holmes C (2010) Association of anosmia with autonomic failure in Parkinson disease. Neurology 74:245–251
Nagayama H, Hamamoto M, Ueda M, Nishiyama Y, Hamamoto M, Katayama Y (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 76:249–251
Hamada K, Hirayama M, Watanabe H, Kobayashi R, Ito H, Ieda T (2003) Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:423–426
Saiki S, Hirose G, Sakai K, Kataoka S, Hori A, Saiki M et al (2004) Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 220:105–111